A Pan-European Post-Authorisation Safety Study: Risk of Pancreatic Cancer Among Type 2 Diabetes Patients Who Initiated Exenatide as Compared With Those Who Initiated Other Non-Glucagon-Like Peptide 1 Receptor Agonists Based Glucose Lowering Drugs

Clinical trial NCT05663515 · RECRUITING

Trial details

NCT number: NCT05663515
Sponsor: AstraZeneca
Status: RECRUITING
Study type: OBSERVATIONAL

Pancreatic Cancer

Start date: 2024-09-30
Primary completion: 2026-10-01
Enrollment: 24000

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.